Future studies will need to consider potential biased agonism by different GLP-1 agonists which could differentially impact GRK-mediated β-arrestin recruitment (14, 16, 29–31) and result in differential pharmacological effects and evaluate the role of GRK inhibition in models with impaired glucose tolerance (24). This evidence concerns the gene GCG and Impaired glucose tolerance.